cIMPACT-NOW: a practical summary of diagnostic points from Round 1 updates
cIMPACT-NOW (the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy) was established to provide a forum to evaluate and recommend proposed changes to future CNS tumor classifications. From 2016 to 2019 (Round 1), cIMPACT published four updates. Update 1 clarified the use o...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
30 April 2019
|
| In: |
Brain pathology
Year: 2019, Jahrgang: 29, Heft: 4, Pages: 469-472 |
| ISSN: | 1750-3639 |
| DOI: | 10.1111/bpa.12732 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1111/bpa.12732 Verlag, lizenzpflichtig, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/bpa.12732 |
| Verfasserangaben: | David N. Louis; David W. Ellison; Daniel J. Brat; Kenneth Aldape; David Capper; Cynthia Hawkins; Werner Paulus; Arie Perry; Guido Reifenberger; Dominique Figarella‐Branger; Andreas von Deimling; Pieter Wesseling |
| Zusammenfassung: | cIMPACT-NOW (the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy) was established to provide a forum to evaluate and recommend proposed changes to future CNS tumor classifications. From 2016 to 2019 (Round 1), cIMPACT published four updates. Update 1 clarified the use of the term NOS (Not Otherwise Specified) and proposed use of the additional term NEC (Not Elsewhere Classified). Update 2 issued clarifications regarding two diagnoses: Diffuse Midline Glioma, H3 K27M-mutant and Diffuse Astrocytoma/Anaplastic Astrocytoma, IDH-mutant. Update 3 proposed molecular criteria that could be used in the setting of an IDH-wildtype diffuse or anaplastic astrocytic glioma without histological features of glioblastoma to infer that the tumor would behave similarly to a grade IV glioblastoma. Update 4 suggested that, in children and young adults, subtypes of IDH-wildtype/H3-wildtype diffuse gliomas may have distinct clinical features in the setting of a BRAFV600E mutation, FGFR1 alteration, other MAPK pathway alteration, or a MYB or MYBL1 rearrangement. The practical diagnostic relevance of these cIMPACT proposals is highlighted in this summary. |
|---|---|
| Beschreibung: | Gesehen am 03.04.2020 |
| Beschreibung: | Online Resource |
| ISSN: | 1750-3639 |
| DOI: | 10.1111/bpa.12732 |